MITF and melanoma: In this respect, the MITF-depleted phenotype and the MITFhigh phenotype of melanoma cells can be acquired or enriched during the development of resistance to BRAFi/MEKi [164,165], suggesting that a more comprehensive and multimodal assessment of the phenotype of resistant melanoma cells is needed to predict the potential efficacy of either copper chelators or copper ionophores and copper-containing nanodrugs.